Recent advances and research in hemodialysis. BDTT-023-c Unit-C a. Noc

Recent advances and research in hemodialysis. BDTT-023-c Unit-C a. Nocturnal dialysis. b. Online dialysis. c. Daily dialysis. BDTT-023-d Unit-D Telemedicine in dialysis practice. BDTT-023-e Unit-E Introduction to kidney transplantation immunology, procedure and Immunosuppressive medications. BDTT-023-f Unit-F Live donor and cadaver transplantation; paired exchange transplantation and ABO incompatible transplantation; transplant in sensitized recipients. Explain each in detail extract from dialysis book

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Searching the Web

online hemodiafiltration hemodialysis advances telemedicine dialysis 2024 2025

Reading File

Searching the Web

ABO incompatible kidney transplantation paired exchange sensitized recipients desensitization 2024

Searching PubMed

"hemodiafiltration" AND "hemodialysis" AND mortality

Searching PubMed

"kidney transplantation" AND "paired kidney exchange" AND "ABO incompatible"

All four units are now comprehensively covered. Here is a recap of what each section contains:

What was covered:

Unit C — Hemodialysis Modalities:

Nocturnal dialysis: 6–8 hour overnight sessions; FHN Nocturnal Trial showed improved secondary outcomes (BP, phosphate, weight) but primary composite not met; safety improved by remote monitoring and blood-leak detectors
Online Hemodiafiltration (OL-HDF): High-volume convective + diffusive therapy; the landmark CONVINCE RCT (NEJM 2023) showed 23% relative mortality reduction vs. high-flux HD; FDA cleared the Fresenius 5008X in 2024 for U.S. use
Short daily HD: 5–6 sessions/week; FHN Daily Trial met its primary composite (mortality + LV mass); better BP, QoL, phosphate control; requires more frequent vascular access interventions

Unit D — Telemedicine: Remote patient monitoring, AI-driven HD machine connectivity, teleconsultations, precision dialysis with big data/AI (ASN 2025 statement), and nocturnal remote safety systems

Unit E — Transplant Immunology, Procedure, Immunosuppression: HLA/ABO antigen systems, four rejection types (hyperacute → chronic), surgical procedure (heterotopic iliac placement, vascular anastomoses, ureteroneocystostomy), and complete immunosuppression tables (induction: basiliximab/ATG; maintenance: tacrolimus/MMF/steroids; rejection treatment)

Unit F — Special Donor Scenarios: Living vs. deceased (DBD vs. DCD) donors; machine perfusion advances; paired exchange mechanics and national KPD programs; ABO-incompatible desensitization protocol (rituximab + plasmapheresis/IA); sensitized recipient management (virtual crossmatch, bortezomib, daratumumab, eculizumab, UNOS priority allocation)

This is a shared conversation. Sign in to Orris to start your own chat.